Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

Eligibility Criteria

• * Ability to comprehend and willingness to sign a written ICF for the study.
• * Completed the treatment period of a predetermined, Incyte-sponsored, povorcitinib parent study without safety or tolerability concerns, per investigator's assessment.
• * Received clinical benefit from treatment with study drug during the parent study, as determined by the investigator.
• * Demonstrated compliance, as assessed by the investigator, with the parent Protocol requirements.
• * Willingness to avoid pregnancy or fathering children as defined in the protocol.
• * Willingness and ability to comply with the study Protocol and procedures.
• * Had been permanently discontinued from study treatment during the parent study.
• * Had temporary study drug interruption due to safety and/or efficacy reasons at or after the final visit of the parent study.
• * Received at least 1 dose of either of the following therapies within the 28 days prior to starting treatment in this rollover study:
• * Biologic immunomodulator (examples include but are not limited to adalimumab, bimekizumab, dupilumab, infliximab, nemolizumab, secukinumab).
• * Live, attenuated vaccine.
• * Plans for administration of a live, attenuated vaccine during this study or within 8 weeks after the last dose of study drug.
• * Women who are pregnant (or who are considering pregnancy) or breastfeeding.
• * Known hypersensitivity or severe reaction to povorcitinib or excipients of povorcitinib and/or other products in the same class.
• * Currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study.
• * Any condition that would, in the investigator's and/or sponsor's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.